Esoteric Testing Market Technological Advancements, Rising Chronic Diseases, and Personalized <a target=_blank href= ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.

Immunoassay technologies include analytical methods like fluorescence immunoassays, chemiluminescent immunoassays, radioimmunoassays, lateral flow assays, immunofluorescence assays, multiplex ...

The US Food and Drug Administration (FDA) has cleared Revvity’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. The authorisation by the agency marks the first time a ...

(RTTNews) - Revvity (RVTY) received 510(k) clearance from FDA for EUROIMMUN's automated chemiluminescence-based immunoassay test for free testosterone. The company noted that this is the only FDA ...

Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA ...

Comprehensive Assay Portfolio: Beyond traditional chemiluminescence applications, it supports advanced diagnostics for specialized conditions such as stroke, Alzheimer's disease, thrombosis, and ...